Physician profile
Rodney A Marcom
NPI 1588631659
$5,857.13
in general payments reported to CMS, 2019-2025
42 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $190 · 2021: $780 · 2022: $519 · 2023: $1,405 · 2024: $1,318 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,967.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $579.59 | 2020-2025 | Farxiga, Fasenra, Breztri |
| Lilly USA, LLC | $567.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $503.30 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $460.45 | 2023-2025 | |
| Abbott Laboratories | $322.25 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $295.71 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $250.28 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $225.77 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.74 | 2019-2023 | Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $170.68 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $149.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $135.72 | 2020-2025 | Verquvo, Belsomra, Capvaxive |
| Eisai INC. | $124.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $95.74 | 2023-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Marcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.